Clinical trial
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus
NCT03134196 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus
- Lead sponsor
- NYU Langone Health
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- August 23, 2017
- Completion date
- July 22, 2024
- Enrollment
- 527 (actual)
- Sites
- 78
Conditions
As the registry lists them; a condition with its own page is linked.